GLP-1 fusion proteins
AssigneeEli Lilly and Company
InventorsWolfgang Glaesner, Radmila Micanovic, Sheng-Hung Rainbow Tschang
Life of this patent
Estimating the term…
Abstract
The present invention relates to glucagon-like-1 compounds fused to proteins that have the effect of extending the in vivo half-life of the peptides. These fusion proteins can be used to treat non-insulin dependent diabetes mellitus as well as a variety of other conditions.
Claims13
A heterologous fusion protein comprising a first polypeptide with a N-terminus and a C-terminus fused to a second polypeptide with a N-terminus and a C-terminus wherein the first polypeptide is a GLP-1 compound and the second polypeptide is selected from the group consisting of
- a) human albumin;
- b) human albumin analogs;
- and
- c) fragments of human albumin,
- and wherein the C-terminus of the first polypeptide is fused to the N-terminus of the second polypeptide.
A heterologous fusion protein comprising a first polypeptide with a N-terminus terminus and a C-terminus fused to a second polypeptide with a N-terminus and a C-terminus wherein the first polypeptide is a GLP-1 compound and the second polypeptide is selected from the group consisting of
- a) human albumin;
- b) human albumin analogs;
- and
- c) fragments of human albumin,
- and wherein the C-terminus of the first polypeptide is fused to the N-terminus of the second polypeptide via a peptide linker.
Dependencies are inferred from the claim text.